Apotex Begins Roll Out Of Avastin Biosimilar In Canada

Product Of The Company’s Strategic Partnership With Mabxience

Following recent Health Canada approval, Apotex has launched partner mAbxience’s Bambevi (bevacizumab) biosimilar across Canada, adding to its portfolio of biosimilars that includes both filgrastim and pegfilgrastim.

Canadian flag waving_567680776_1200
Bambevi was approved by Health Canada earlier this year • Source: Shutterstock

Apotex’ Apobiologix biosimilars unit says it “looks forward to further expansion of the portfolio to ensure we continue to support patient needs,” after launching the Bambevi (bevacizumab) biosimilar across Canada, the company’s “first oncology therapeutic treatment.”

In late September Apotex announced Health Canada approval for the biosimilar to Avastin, a product of the company’s strategic partnership...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.